key: cord-0963426-o53ou2dy
authors: Stewart, C. Allison; Gay, Carl M.; Ramkumar, Kavya; Cargill, Kasey R.; Cardnell, Robert J.; Nilsson, Monique B.; Heeke, Simon; Park, Elizabeth M.; Kundu, Samrat T.; Diao, Lixia; Wang, Qi; Shen, Li; Xi, Yuanxin; Zhang, Bingnan; Della Corte, Carminia Maria; Fan, Youhong; Kundu, Kiran; Gao, Boning; Avila, Kimberley; Pickering, Curtis R.; Johnson, Faye M.; Zhang, Jianjun; Kadara, Humam; Minna, John D.; Gibbons, Don L.; Wang, Jing; Heymach, John V.; Byers, Lauren Averett
title: Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology
date: 2021-07-16
journal: J Thorac Oncol
DOI: 10.1016/j.jtho.2021.07.002
sha: c5ffa7d260d97f4fcce7655fe1111c845379a1e5
doc_id: 963426
cord_uid: o53ou2dy

COVID-19 is an infectious disease caused by SARS-CoV-2, which enters host cells via the cell surface proteins ACE2 and TMPRSS2. Using a variety of normal and malignant models and tissues from the aerodigestive and respiratory tracts, we investigated the expression and regulation of ACE2 and TMPRSS2. We find that ACE2 expression is restricted to a select population of epithelial cells. Notably, infection with SARS-CoV-2 in cancer cell lines, bronchial organoids, and patient nasal epithelium, induces metabolic and transcriptional changes consistent with epithelial to mesenchymal transition (EMT), including upregulation of ZEB1 and AXL, resulting in an increased EMT score. Additionally, a transcriptional loss of genes associated with tight junction function occurs with SARS-CoV-2 infection. The SARS-CoV-2 receptor, ACE2, is repressed by EMT via TGFbeta, ZEB1 overexpression and onset of EGFR TKI inhibitor resistance. This suggests a novel model of SARS-CoV-2 pathogenesis in which infected cells shift toward an increasingly mesenchymal state, associated with a loss of tight junction components with acute respiratory distress syndrome-protective effects. AXL-inhibition and ZEB1-reduction, as with bemcentinib, offers a potential strategy to reverse this effect. These observations highlight the utility of aerodigestive and, especially, lung cancer model systems in exploring the pathogenesis of SARS-CoV-2 and other respiratory viruses, and offer important insights into the potential mechanisms underlying the morbidity and mortality of COVID-19 in healthy patients and cancer patients alike.

In December 2019, reports of a viral illness with severe respiratory symptoms emerged from Wuhan, China 1,2 . The novel virus was classified as a coronavirus and subsequently named SARS-CoV-2. It exhibited rapid global spread and met the World Health Organization's criteria of a pandemic within three months following the first reported diagnosis (https://covid19.who.int/). As of April 2021, more than 148 million individuals have been infected worldwide with over 3.1 million deaths (covid19.who.int). SARS-CoV-2 infection is the cause of the respiratory illness COVID-19, which presents most frequently with symptoms including cough and dyspnea, accompanied by a moderate to high fever 2, 3 . The severity of patient symptoms following SARS-CoV-2 infection varies widely from asymptomatic carrier-status to critical illness. Given the specific complications associated with infection, it is not initially surprising that patients with cancer and, specifically, thoracic malignancies, seem to experience poorer clinical outcomes 4,5 . However, it is unclear whether these poorer outcomes represent the impact of demographics (e.g. age, smoking status, gender) or cellular and molecular changes associated with the tumor and its microenvironment.

While there are currently no validated molecular biomarkers for susceptibility to, or severity of, SARS-CoV-2 infection, it has recently been described that, as with SARS-CoV, SARS-CoV-2 cell entry requires interactions with angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) on the surface of the host cell 6 . Specifically, ACE2 binds to a subunit of the SARS-CoV-2 spike (S) protein, while TMPRSS2 is responsible for S-protein cleavage, or priming, to allow fusion of viral and host cellular membranes 6 . Differences in these receptors has been described in certain populations harboring higher allelic frequency of mutations and coding variants associated with higher ACE2 expression 7 . Notably, ACE2 has previously been shown to exert a protective effect toward the development of acute respiratory distress syndrome (ARDS)one of the most common and lethal complications of SARS-CoV-2 infection 8, 9 . Given the propensity for ARDS in SARS-CoV-2 infected patients, this protective effect initially seems paradoxical, but previous data on SARS-CoV-1 suggest that subsequent to infection ACE2 expression is downregulated, thus tipping the balance in favor of acute lung injury 10 .

As the presence of ACE2 and/or TMPRSS2 may be rate-limiting for SARS-CoV-2 infection, we utilized bulk and single-cell transcriptional data from a combination of normal and malignant tissue samples and models from the aerodigestive and respiratory tracts to explore mechanisms governing the expression of ACE2 and TMPRSS2. These data were assembled from a variety of sources, including current and previous work from our laboratory, department and datasets generated as part of our longstanding joint UT Southwestern/MD Anderson Cancer Center NCI Lung SPORE program, as well as from public datasets derived all around the world and represent a novel repurposing of data to understand more of ACE2 expression, as well as consequences of infection. Our bulk data suggests that aerodigestive and lung cancer cell lines have a broad range of ACE2 and TMRPSS2 expression and would serve as good models for studying SARS-CoV-2 infection, consistent with the observation that SARS-CoV-2 virus has the ability to infect several lung cancer cell lines (e.g., Calu-3 and A549) 6, 35 . Furthermore, while the normal aerodigestive and respiratory tracts represent key points of viral entry and infection, limiting an investigation to normal tissue may unnecessarily limit available samples for analysis and, especially, limit the range of cellular and molecular phenomena represented by those samples.

Meanwhile, single-cell analyses demonstrate that while TMPRSS2 is widely expressed in normal respiratory epithelium, ACE2 expression is limited to a small collection of cells 36 and, therefore, may be a limiting factor for infection or drive dependence on other mechanisms, such as putative AXL-mediated cell entry [37] [38] [39] [40] [41] . There have been numerous reports of patients developing loss of chemosensation (taste, smell, etc.) following SARS-CoV-2 infectionan observation that pointed to another small collection of cells 42, 43 . Tuft, or brush, cells are rare chemosensory cells present in the aerodigestive and respiratory tracts, among other sites, that mediate taste and smell, along with innate immune response 44, 45 . These cells, which are epithelial in nature, strongly express POU2F3, a transcription factor that is also highly expressed in certain lung cancers, including a subset of small cell lung cancer 46-49 . Our analyses indeed suggest that ACE2 expression is enriched in tuft cells compared to non-tuft cells within the respiratory tract. However, this was not absolute and, thus, we considered broader regulatory mechanisms that might govern ACE2 expression. Previous literature has proposed, inconsistently, both positive and negative associations between ACE2 expression and epithelial differentiation 50, 51 , while tuft cells, in which ACE2 is enriched in our analysis, are highly epithelial 45 . We assessed the relationship between ACE2 and epithelial differentiation in numerous aerodigestive and respiratory datasets, and found striking and consistent positive correlations with transcriptional, microRNA, and metabolic signifiers of epithelial differentiation in virtually all datasets analyzed.

Finally, we consider the role that regulators of epithelial to mesenchymal transition (EMT) may play in modulation of ACE2 expression. EMT is a well-characterized phenomenon critical to normal developmental processes, but co-opted by tumor cells to promote metastasis and resistance to treatments ranging from chemotherapies to radiation 52 . We provide evidence that the miR-200 familyzinc finger E-box-binding homeobox 1 (ZEB1) pathway, which is an established regulator of EMT 53,54 , also directly regulates ACE2 expression, likely via putative ZEB1 repressor sites located in the ACE2 promoter. Furthermore, we highlight that SARS-CoV-2 infection both in vitro and in patients yields increased expression of EMT-associated genes, including ZEB1 and AXL and metabolic derangements (e.g. a shift away from glutamine and toward glutamate) characteristic of EMT 55,56 . Inhibition of AXL, a mesenchymal receptor tyrosine kinase, with bemcentinib both induces ACE2 and represses ZEB1 and may serve as a therapy to shift SARS-CoV-2 infected cells away from a mesenchymal phenotype (i.e., reverse EMT). Additionally, viral infection of epithelial cells, which are glutamine-dependent with high GLUL expression and presumably more metabolically-primed for replication, promotes rapid replication due to the enhanced dependence on glutamine for nucleotide synthesis and subsequently depletes glutamine stores 56 .Other viruses have been shown to induce host cell metabolic reprogramming to satisfy the biosynthetic and energy requirements needed for replication [57] [58] [59] [60] .

The association between EMT and lung injury/ARDS has been described previously, with the central pathogenesis being the breakdown of the alveolar-epithelial barrier, due in part to disruption of tight junctions [61] [62] [63] . Furthermore, EMT is also known to downregulate tight junction components, including several members of the Claudin protein family 64 . Claudins are integral membrane proteins localized at tight junctions that are involved in regulating epithelial cell polarity and paracellular permeability. Intriguingly, previous data demonstrated that overexpression of miR-200 family members (which inhibit ZEB1 expression) or direct exogenous silencing of ZEB1 has a protective effect in a murine, lipopolysaccharide-induced model of ARDS 65 . In this context, our findings support a novel model for the pathogenesis of SARS-CoV-2 in which the virus initially infects a small pool of highly epithelial cells of the aerodigestive and respiratory tracts followed by those infected cells undergoing molecular alterations typical of EMT (i.e., ZEB1/AXL upregulation). These EMT-like alterations, in turn, result directly in the down-regulation of genes associated with tight junctions and, in doing so, eradicate the proposed ARDS-protective effect of these epithelial, ACE2-positive cells.

Datasets from multiple sources were utilized in these analyses, including those publicly available in GEO datasets, as well as those generated by our lab, department and the longstanding joint UT Southwestern.MD Anderson Cancer Center NCI Lung SPORE program . The publicly available data includes sets such as The Cancer Genome Atlas (TCGA), an NCI resource established for data discovery and hypothesis testing. A rigorous analysis of data quality was performed prior to inclusion. No comparisons were made across datasets. None of the comparisons or queries were previously performed or published.

ACE2 is widely expressed in normal tissues from Genotype-Tissue Expression (GTEx) Project (http://www.gtexportal.org) and was highest in testis and small intestine and lowest in spleen and blood with moderate expression in lung and salivary glands, which are sites of SARS-CoV-2 transmission and/or infection (Supplemental Figure 1a) . Transcriptional data is shown as normalized relative gene expression..

To leverage cancer cell lines and patient tumors to SARS-CoV-2 research, we explored expression of the receptors, ACE2 and TMPRSS2, and discovered a negative correlation with EMT. This was validated in SARS-CoV-2-infected samples and led to investigation of ways to manipulate EMT in an effort to minimize infection and/or ARDS in patients ( Figure 1a ). ACE2 expression in aerodigestive and respiratory cancer cell lines ( Figure 1b ) and both normal and tumor specimens (Figure 1c ) is consistently higher in specimens with a low EMT score, suggesting that ACE2 is primarily expressed by epithelial cells in these cancers [11] [12] [13] [14] [15] [16] [17] [18] [19] [66] [67] [68] . The EMT score uses 76 genes to define the degree to which cells or tissues have undergone EMT and has been applied in TCGA projects [69] [70] [71] . This observation is confirmed by a consistent negative correlation of ACE2 and EMT score in all nine cell line and tumor data sets (Table 1) . TMPRSS2, the protease also required for SARS-CoV-2 infection, is similarly expressed in models with epithelial gene signatures (Figure 1b ,c) and highly correlated with ACE2 expression in cancer models (Table 1) . To determine whether expression levels of ACE2 were different in normal tissues and tumors, we compared expression in TCGA tumor datasets with paired normal, adjacent samples. Both normal and lung adenocarcinoma (LUAD) tissues have similar ACE2 expression (TCGA LUAD P=0.21) and EMT score (TCGA LUAD P=0.87) (Supplemental Figure 1b) , although a greater range of expression (both higher and lower) could be observed in tumors [72] [73] [74] . Interestingly, and in contrast to some previous reports, no difference in ACE2 expression was detected in normal lung tissue (adjacent to TCGA LUAD) with regards to smoking status, gender or age (Supplemental Figure 1c ).

In addition to ACE2 mRNA expression, we screened a cohort of NSCLC and SCLC cell lines for ACE2 protein levels by reverse phase protein array (RPPA; Figure 1d ) and within a subset of NSCLC cell lines we analyzed cell surface expression of NSCLC cell lines by flow cytometry (Figure 1e ). Similar to gene expression, ACE2 levels negatively correlate with mesenchymal proteins, including vimentin (Supplemental Figure 1d ). To go beyond the quantitative, genebased EMT score, we investigated expression of ACE2 mRNA compared to specific epithelial (i.e., E-cadherin, RAB25, beta-catenin) or mesenchymal (i.e., vimentin, ZEB1) proteins by RPPA analysis. ACE2 was higher in non-small cell lung cancer (NSCLC) cell lines (P<0.008) and TCGA tumors (P<0.001; Figure 1f ) with higher levels of epithelial proteins, consistent with the mRNA associations and EMT score.

Our analyses reveal that ACE2 is only expressed by a small subset of cells (0-4.7%) at the single-cell transcriptional level in normal respiratory tissues, as well as in oral cavity tumors and lung cancer xenograft models (Table 2) [30] [31] [32] [33] 75 . However, in all datasets, the rare, ACE2-positive cells consistently have a low, or more epithelial, EMT score. In both fibrotic and donor lung samples, TMPRSS2 is more widely expressed than ACE2, while ACE2 expression is found more frequently in TMPRSS2-positive cells (Figure 1g , Supplemental Table 1 ) relative to TMPRSS2-negative cells. As studies suggest both are required for infection, these data, indicate that ACE2 expression is more limiting than TMPRSS2 expression for SARS-CoV-2 infection within respiratory epithelium.

POU2F3 is a marker of tuft cell expression and is correlated with ACE2 expression in many aerodigestive and lung cancer data sets (Table 1 ). ACE2 protein levels also correlate with POU2F3 in both NSCLC (Rho=0.221, P=0.01) and SCLC (Rho=0.673, P<0.0001) cell lines. Similar to the observation for co-expression with TMPRSS2, ACE2 expression is more often detected in POU2F3-positive than negative cells (Figure 1g , Supplemental Table 1 ). This suggests that tuft cells may be preferentially targeted by SARS-CoV-2 infection in aerodigestive tissues. These rare, ACE2-positive cells can be visualized in tSNE space (Supplemental Figure  2a ) and demonstrate a low EMT score on a cell-by-cell basis in both donor and fibrotic lung samples ( Figure 1h ) and oral cavity tumors (Supplemental Figure 2b ). These ACE2-positive cells are localized within epithelial cell clusters with low EMT score that primarily consist of alveolar type II, ciliated and club cells (Supplemental Figure 2c) 

We next sought to determine the impact of SARS-CoV-2 infection on the EMT status of the infected cell. We analyzed RNAseq data from NSCLC cell lines (A549 and Calu-3) infected for 24h with SARS-CoV-2 (GSE147507) 25 . These are cell lines that are frequently used for lung cancer research. Since A549 cells have low endogenous levels of ACE2 expression, likely due to their mesenchymality, the authors additionally transduced these cells with a vector overexpressing human ACE2 to improve infection. Expression of the epithelial gene EPCAM was An alternative EMT regulator, AXL, which is a TAM (Tyro3, AXL, Mer) family receptor tyrosine kinase strongly associated with a mesenchymal phenotype, has emerged as a key determinant of therapeutic resistance in NSCLC and other cancer types 69, 76 . Similar to ZEB1, AXL is inversely correlated with ACE2 in cell line and tumor samples (Table 1) We next investigated whether SARS-CoV-2 infection directly altered Claudin expression. CLDN2 is expressed in respiratory epithelium, but a role in mediating alveolar edema has not been described 77 To determine whether longer exposure to virus may induce additional EMT changes, we analyzed RNAseq data from human bronchial organoids developed from commercially available, cryopreserved adult bronchial epithelial cells infected with SARS-CoV-2 for five days (GSE150819) 27 . There was a subtle increase in both ZEB1 (P=0.12) and AXL (P=0.14), as well as other mesenchymal genes, including VIM (FC=1. 56 Finally, to evaluate whether viral-induced EMT also occurs in patients, we analyzed metagenomic next-generation sequencing data of human nasopharangeal swabs from 430 PCR-confirmed SARS-CoV-2 and 54 negative control individuals (GSE154770) 28 . SARS-CoV-2 infection downregulated expression of EPCAM (P<0.0001) and upregulated ZEB1 (P<0.0001) and AXL (P<0.0005; Figure 2d ). Similar patterns were found with other epithelial genes, including RAB25 (FC=-2.35; P<0.0001) and CTNNB1 (FC=-3.38; P<0.0001) or mesenchymal genes, including ZEB2 (FC=8.14, P<0.0001). As expected, viral infection was associated with an increased EMT score (P<0.0001; Figure 2d 

To connect differences in ACE2 expression to a more specific EMT regulatory program, we investigated miRNAs in both lung cancer and head and neck cell lines and tumor samples. Interestingly, miRNAs from the miR-200 family were consistently positively correlated with ACE2 78 . As expected, given their known role as inhibitors of EMT, high miR-200 family expression was seen in cells and tumors with high CDH1 (an epithelial-specific marker) and low EMT score and ZEB1, the latter a transcriptional promoter of EMT and target of miR-200 family ( (Table 1) . ACE2 similarly is negatively correlated with a number of other EMT-associated genes, including ZEB2, SNAI1, SNAI2, TWIST1, and CDH2 (Supplemental Table 2 ). While these correlations are almost invariably negative, as expected, none of these genes demonstrate a negative correlation as robust and consistent across datasets between ACE2 as EMT score or ZEB1.

To determine whether transformation from an epithelial to mesenchymal phenotype (EMT) directly alters ACE2 expression, we utilized various methods to induce EMT, including treatment with TGFβ, overexpression of ZEB1, and EGFR TKI resistance. Two highly epithelial NSCLC cell lines cultured with TGFβ for 3 to 5 weeks 20 , increased the EMT score (Supplemental Figure  4a) . Induction of EMT resulted in a loss of ACE2 in H358 and HCC827 (P=0.03 and P=0.06, respectively; Figure 3c ). Additionally, both cell lines exhibited increased ZEB1 following EMT induction (P<0.0001; Figure 3d ). The experiment also included EMT induction in A549 cells, but this line is more mesenchymal with low endogenous ACE2 expression at baseline and TGFβ was unable to reduce already minimal ACE2 (P=0.23, data not shown).

Accordingly, NSCLC and head/neck squamous cell carcinoma (HNSCC) cell lines demonstrate an inverse correlation between ACE2 and ZEB1 ( Figure 3e ). Computational investigation of the ACE2 promoter using the JASPAR database revealed five putative ZEB1 binding sites, suggesting that ZEB1 may directly repress ACE2 expression 80 . Two of these predicted binding sites (ZEB1-EBOX3, ZEB1-EBOX4) were confirmed by chromatin immunoprecipitation (ChIP)seq to be functional binding sites for ZEB1 in the ACE2 promoter in HepG2, a hepatocellular cell line (Supplemental Figure 4b) . Consistent with this, induction of EMT via over-expression of Zeb1 in 393P murine lung adenocarcinoma cells results in a more than 2fold reduction in Ace2 expression (P=0.091; Figure 3f ) 21 . Furthermore, constitutive overexpression of ZEB1 in HCC827 cells 21, 81, 82 reduced cell surface expression of ACE2 compared to either the parental cell line (P=0.05) or the vector control (P=0.07; Figure 3g ). As expected, overexpression of ZEB1 increased vimentin levels (compared to parental, P<0.0001 or vector control, P=0.002; Figure 3h ). ACE2 is repressed by EMT and this is mediated, at least in part, by ZEB1.

EGFR-mutated NSCLCs are routinely and effectively treated with EGFR TKIs, but resistance inevitably develops via characteristic mechanisms including secondary EGFR resistance mutations (i.e. T790M) and, notably, EMT 83 . Thus, we evaluated expression of ACE2 in EGFRmutated NSCLC cells (HCC4006 and HCC827) treated with the EGFR TKI erlotinib until resistance occurred 22 . ACE2 and TMPRSS2 were downregulated in EGFR TKI resistant lines that had undergone EMT in comparison to parental (EGFR TKI sensitive cells) (Figure 3i) . Separately, PC-9 cells which also harbor EGFR activating mutations and display high baseline levels of ACE2 were treated with the EGFR TKI gefitinib for three weeks until resistance emerged through EMT 23 or though acquired T790M resistance mutations 24 . ACE2 was downregulated in gefitinib-resistant cells that had undergone an EMT but not in resistant T790M+ resistant cells that maintained an epithelial phenotype. (Figure 3i ). These findings are consistent with the notion of ACE2 repression by the EMT-regulator ZEB1. In xenograft models, mice bearing PC-9 xenograft tumors treated with vehicle or the EGFR TKI osimertinib for three weeks to induce resistance through EMT were transcriptionally profiled by single-cell RNAseq 33 . ACE2 was only detectable in vehicle-treated tumor cells, suggesting that ACE2 expression was lost in tumors that had undergone EMT.

To identify metabolic features of cells able to be infected by SARS-CoV-2, metabolites associated with ACE2 expression were investigated. ACE2 expression correlates with glutamine in upper aerodigestive tract cell lines (P<0.01; Supplemental Figure 4d ) 84 and ACE2 levels correlate with glutamine in a subset of NSCLC cell lines (rho=0.89, P=0.02; Supplemental Figure 4e ) Consistent with this finding, ACE2 expression correlation with a list of 253 metabolism-associated genes and GLUL, which encodes an enzyme (glutamine synthetase) responsible for conversion of glutamate to glutamine, was identified in NSCLC, HNSCC, and SCLC cell lines (Supplemental Figure 4f) and was confirmed in the tumor data sets (Table 1 ). In addition to GLUL, DERA (deoxyribose-phosphate aldolase) and SLC6A14 (solute carrier family 6 member 14) were identified and are implicated in nucleotide metabolism and amino acid (including glutamine) transport, respectively (Supplemental Figure 4f) . Interestingly, GLS, which encodes the enzyme (glutaminase) that catalyzes the opposing reaction, in which glutamine is converted to glutamate, is negatively correlated with ACE2 expression (Table 1 ). Next, we evaluated whether ZEB1 is a regulator of metabolism. Unlike Ace2, Zeb1 is unable to directly regulate Glul expression in murine 393P cells overexpressing Zeb1 (P=0.23, Supplemental Figure 4g ). This was confirmed by ZEB1 gene silencing and overexpression analyses (data not shown), suggesting that the metabolic changes are not directly controlled by ZEB1. Interestingly, GLUL was downregulated in EGFR TKI gefitinib-resistant cells that had undergone an EMT but not in resistant T790M+ resistant cells that maintained an epithelial phenotype. (Figure 3i) . Similarly, GLUL expression was reduced following osimertinib-resistance that occurred through EMT (Supplemental Figure 4c) . Taken together, glutamine synthetasecatalyzed conversion of glutamate to glutamine in epithelial cells aims to increase production of amino acids and nucleotides, while in mesenchymal cells, glutaminase converts glutamine to glutamate to preferentially shift toward the tricarboxylic acid (TCA) cycle, thus priming epithelial cells for viral infection.

NSCLC encompasses a heterogeneous group of lung cancers with unique molecular features. To determine whether any previously characterized NSCLC subsets were linked to differential ACE2 expression, we compared common driver mutation subsets of the TCGA LUAD tumors and found that EGFR-mutant LUAD tumors had significantly higher ACE2 expression (P=0.001; J o u r n a l P r e -p r o o f Supplemental Figure 4h ). EGFR-mutated tumors have constitutive activation of the epidermal growth factor receptor (EGFR) and downstream signal transduction pathway. Accordingly, higher ACE2 expression was associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs), as visualized by drug target constellation (DTECT) map (Supplemental Figure  3i) . Moreover, ACE2 expression was broadly correlated with increased expression of several EGFR/HER family members, including EGFR, ERBB2 and ERBB3 in cell lines and tumors (Supplemental Figure 3j) , consistent with its preferential expression in epithelial cells. A similar link between EGFR inhibition and COVID-19 patients has been described previously 85 .

We hypothesized that bemcentinib (BGB324, or R428), an inhibitor of the mesenchymal receptor tyrosine kinase AXL with a known anti-viral effect, may offer therapeutic benefit through a reversal of EMT 86 . Bemcentinib downregulated ZEB1 expression in mesenchymal cell lines, 393P overexpressing Zeb1 (P=0.003) and Calu-1 (P=0.21) (Figure 4a ). In Calu-1 cells, bemcentinib also downregulated vimentin and upregulated both E-cadherin and ACE2. Similarly, 48h of bemcentinib-treatment in HCC827 parental, vector control, and ZEB1 constitutive overexpressing lines 21,81,82 induced ACE2, as confirmed by densitometry normalized to vinculin controls (Figure 4b ). In contrast, hydroxychloroquine treatment was unable to consistently alter ACE2 or GLUL levels in a range of NSCLC cell lines (Figure 4c ), indicating that this treatment is unable to alter EMT.

Together, these data suggest a potential model in which SARS-CoV-2 infects rare, epithelial, ACE2-and TMPRSS2-positive cells in the aerodigestive and respiratory tracts that are metabolically-primed for glutamine synthesis and rapid replication (Figure 4d ). Once a cell is infected with SARS-CoV-2, there is a shift to a more mesenchymal phenotype characterized by high ZEB1 and AXL, putatively lower levels of miR-200, and a decreased dependence on glutamine synthesis. Viral infection and the resultant mesenchymal shift and ZEB1 increase may have devastating implications on the risk and pathogenesis of ARDS in COVID-19 patients (Figure 4d ).

The ultimate public health impact of the SARS-CoV-2 pandemic has not yet been fully realized. While increased molecular understanding of the virus-host interactions is sorely needed, the impact of the pandemic itself has created practical limitations on laboratory-based research due to wide-ranging institutional restrictions. Despite these restrictions, an unprecedented collaborative research effort has ensued, with little regard for geographic and public-private boundaries that so often impose their own limitations. In the study above, we present an effort that not only incorporates our own unique cancer data sets, but also utilizes a plethora of publicly available data from basic scientists, clinicians, and bioinformaticians around the world including both normal and malignant tissues. The linkage of regulation of ACE2 expression and EMT, the latter an uncommon phenomenon in normal tissue, but well-defined in cancer cells, highlights the value of considering malignant tissue and models for the investigation of SARS-CoV-2. While tumor tissues and models undoubtedly have unique genetic and epigenetic features not routinely observed in non-malignant SARS-CoV-2 infected cells in patients, many regulatory pathways and cellular behaviors, including those involved in EMT are conserved between normal and malignant settings. Malignant tissues, however, offer a significant advantage over normal tissues in that they have been extensively profiledgenomically, transcriptomically, and proteomically, including in circumstances in which processes such as EMT have been manipulated. The extent of available malignant tissue and model data, thus, allowed us to develop and preliminarily pursue novel hypotheses related to SARS-CoV-2 in datasets that were largely published prior to the emergence of the virus itselfanother vital advantage when investigating a novel pathogen.

In this study, we describe a novel model for the regulation of ACE2, which others have shown is essential for the host cell entry of SARS-CoV-2 6 . In contrast to reports of patient susceptibility to SARS-CoV-2 due to age, gender, smoking history, or thoracic malignancies 4,5,87,88 we were unable to identify consistent differences in ACE2 expression on the basis of these variables. Our data suggest that ACE2 expression is restricted in both normal and malignant aerodigestive and respiratory tissues almost exclusively to epithelial cells, including highly specialized POU2F3-positive tuft cells, and that this restriction reflects regulatory mechanisms shared with EMT. While others have observed a putative relationship in other contexts between ACE2 and EMT, these observations were inconsistent, supporting roles for ACE2 as an inducer and an inhibitor of EMT 50, 51 . In virtually all explored datasets, ranging from cancer cell lines to normal respiratory tissue, we observed a strong and consistent negative correlation between ACE2 expression and EMT. This relationship is observed even on a cell-by-cell basis, as scRNAseq illustrates that virtually every cell with detectable ACE2 expression is epithelial based on our published EMT score 70 .

The negative correlation between EMT and ACE2 was not limited to expression analyses, as metabolomic analysis revealed that ACE2 expression is strongly correlated with high levels of glutamine and the expression of GLUL, the enzyme responsible for the conversion of glutamate to glutamine. High levels of glutamine are characteristic of epithelial differentiation, while a shift from glutamine to glutamate is associated with EMT. We propose that SARS-CoV-2 targets these ACE2-expressing, metabolically-primed epithelial cells, in order to exploit the abundant nucleotides for rapid replication and viral spread. The consequence of SARS-CoV-2 infection is induction of EMT and subsequent upregulation of GLS, resulting in a depletion of glutamine following SARS-CoV-2 infection in patients 56 .

Our subsequent analyses demonstrate that, beyond mere correlations, various strategies to manipulate EMT result in predictable alterations in the expression of ACE2. For example, treatment of cells with TGFβ or overexpression of ZEB1 induces EMT and decreased expression of ACE2. Similarly, in EGFR-mutant lung adenocarcinoma, in which there is relatively higher ACE2 expression, prolonged treatment with an EGFR-targeting TKI may result in multiple mechanisms of therapeutic resistance, of which EMT is a common one. Our results demonstrate that ACE2 is downregulated when EMT is the underlying resistance mechanism, but not when resistance emerges due to development of secondary resistance mutations in EGFR. Coincident with the loss of ACE2 expression is the downregulation of GLUL, to promote glutamate and enable production of TCA intermediates and energy.

EMT is a complex process regulated by an intricate molecular network and we hoped to discern whether any of the specific pathway(s) that regulate EMT also mediate ACE2 expression. An investigation into one of the transcriptional mechanisms underlying EMT and its association with ACE2 revealed consistent positive correlations across tissue and sample types with the miR-200 family of microRNAs. The miR-200 family has a well-established role as an inhibitor of EMT via the downregulation of the transcriptional repressor ZEB1. Predictably, a strong negative correlation was observed between ACE2 and ZEB1. The repression of ACE2 by ZEB1 is mediated via two repressor binding sites for within the ACE2 promoter and forced overexpression of ZEB1 results in a more than two-fold decrease in ACE2 expression, but not GLUL. ZEB1 regulation occurs via SNAI1 and/or TWIST1 while SNAI1 induces nuclear translocation of ETS1, which is required for ZEB1 expression 89 . It is likely that EMT induction of these genes by SARS-CoV-2 results in increased ZEB1. Finally, we observed that SARS-CoV-2 infected lung cancer cell lines, bronchial organoids and patient nasopharangeal swabs demonstrate significant shifts toward several EMT-like features including upregulation of ZEB1 and downregulation of EPCAM.

Together, our data, in the context of the ever-growing literature on SARS-CoV-2, suggest that ACE2 expression is necessary for initial viral entry and, therefore, is relatively high in those cells infected by the virus. These cells are epithelial and, in our data sets, unexpectedly rare, considering the devastating impact of this infection. Following viral entry, however, SARS-CoV-2 infection induces molecular changes within the cells that are reminiscent of EMTespecially the increased expression of ZEB1. These SARS-CoV-2-induced changes, compounded by the downregulation of genes, including tight junction components, which play a critical role in restricting epithelial and endothelial permeability, exposes respiratory cells to increased risk of edema and ARDS. Interestingly, previous reports with SARS-CoV(-1) demonstrate that lung cells, including alveolar epithelial cells, express higher levels of TGFβ, a key regulator of EMT 90 . It is not surprising that a similar mechanism would occur with a similar coronavirus, such as SARS-CoV-2.

While these data demonstrate an intriguing mechanism for the molecular virus-host interaction, it is critical to consider how these observations may be harnessed to develop strategies to improve patient outcomes. This, as always, is complex. Would a therapeutic effort focused on prevention of the initial infection by decreasing ACE2 levels, for example with an inhibitor of the miR-200 family, have unforeseen consequences such as increased risk of ARDS? Similarly, would therapeutic efforts post-infection aimed at preventing SARS-CoV-2 induced ACE2 downregulation, for example with a miR-200 mimetic, serve to place adjacent, newly ACE2positive cells at risk for infection? Several large cohort observational studies on ACE inhibitors and angiotensin II receptor blockers (ARBs), which upregulate ACE2 expression, did not show association with either SARS-Cov-2 infection or risk of severe COVID-19 91 . Interestingly, a human recombinant soluble ACE2 which has already been tested in phase 1 and phase 2 clinical trials for ARDS showed inhibition of SARS-CoV-2 infection in human capillary organoids and human kidney organoids 92 .

Based on the findings in our study, an attractive alternative therapeutic strategy would be to reverse EMT with an AXL inhibitor. AXL is overexpressed in several solid and hematologic malignancies, including non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), breast and prostate cancer, among others. In the context of malignancy, AXL overexpression can drive EMT, tumor angiogenesis, and decreased antitumor immune response 76 . Furthermore, AXL inhibitor, gilteritinib, was identified to have anti-viral activity against SARS-CoV-2 93 . Bemcentinib, a highly selective and potent inhibitor of AXL, currently being tested in phase 2 trials in various malignancies including NSCLC, AML and breast cancer. In preclinical models, bemcentinib has already demonstrated potent anti-viral activity in Ebola and Zika viruses 38, 94 . Recent data suggests that bemcentinib inhibits SARS-CoV-2 viral entry into cells and also prevents inhibition of type I interferon, which is the host cells' innate antiviral immune response. In contrast to AXL inhibition, hydroxychloroquine, an alternative treatment for COVID-19 patients, does not demonstrate any ability to reverse EMT. Accordingly, a Phase II clinical trial (BGBC020) recently completed accrual of 115 patients, assessing the efficacy and safety of bemcentinib for the treatment of hospitalized COVID-19 patients alone or in combination with standard of care 95 . This trial reported a numerically lower number of deaths in the bemcentinib arm (1 death in 28 patients) compared to standard of care (5 deaths in 32 patients), supporting our hypothesis that reversal of EMT in combination with antiviral activity warrants further investigation as a treatment for patients with clinically significant SARS-CoV-2 infection 96 . Separately, a recent report independently identified both bemcentinib (AXL inhibitor) and dacomitinib (EGFR inhibitor) as possessing SARS-CoV-2 antiviral properties out of 3,000 drugs screened 97 . This data supports our findings that EMT reversal by bemcentinib may augment the antiviral activity of AXL inhibitors against SARS-CoV-2, resulting in additional clinical benefit for COVID19 patients.

RNAseq analysis datasets from normal tissues were obtained from GTEx Portal (http://www.gtexportal.org) and tumor samples were retrieved from published and unpublished datasets in multiple human tissues, including TCGA LUAD 11 , TCGA HNSC 12 , TCGA LUSC, PROSPECT 13 , BATTLE 1 14 , and BATTLE 2 15 . Cell line RNAseq data were obtained from multiple sources, including CCLE upper aerodigestive tract (n=32), LCNEC cell lines (n=15) 16 , as well as NSCLC (n=88) 17, 18 , HNSCC (n=70) 19 , and SCLC (n=62) 68 .

Transcriptional data from experimental datasets were publicly available, including EMT induction by three weeks of TGFβ 20 , 393P murine cells with Zeb1 overexpression 21 , erlotinibresistance via EMT in EGFR-mutated HCC4006 and HCC827 NSCLC cell lines 22 , gefitinibresistant PC-9 cells via EMT 23 , T790M-mediated gefitinib-resistance in PC-9 cells 24 , Calu-3 or A549 transduced with a vector expressing human ACE2 were mock infected or infected with SARS-CoV-2 (USA-WA1/2020) 25 , forced miR-200 expression in 344SQ lung adenocarcinoma cells with high metastatic potential 26 , human bronchial organoids were infected with SARS-CoV-2 for five days 27 , and nasopharangeal swabs from patients with positive or negative SARS-CoV-2 PCR results 28 .

Single-cell RNAseq data were obtained from publicly available sources, including bronchial epithelial cells obtained by bronchial brushings from six never smokers and six current smokers 29 , oral cavity tumors from 18 tumors 30 , five normal donor and eight fibrotic lungs 31 , freshly resected parenchymal lung tissue from three patients 32 , bronchial biopsy, nasal brushing, nasal turbinate specimens (GSE121600), and PC-9 EGFR-mutant NSCLC cell xenograft tumors treated with vehicle or osimertinib for three weeks 33 .

ChIPseq analysis of ZEB1 binding in the ACE2 promoter of HepG2, human hepatocyte carcinoma cells, as previously described 34 .

J o u r n a l P r e -p r o o f One million cells each for HCC2302, H3255, HCC827, H1944, H441, H2023, HCC364, A549, H1355, HCC827 vector, and HCC827 ZEB1 were surfaced stained for ACE2 (Santa Cruz; sc-390851) then fixed in 2% PFA and permeabilized using 1X Intracellular Staining Perm Wash Buffer (BioLegend; 421002) prior to intracellular staining for Vimentin (BD Pharmingen; 562338). Samples were analyzed on a BD LSRFortessa Flow Cytometer and data was analyzed using FlowJo 10.7.1. Graphs and statistical analysis were done using GraphPad Prism 8.

One million cells each for 393P ZEB1 (DMSO 16h), 393P ZEB1 (DOX 16h), H441, H1944, HCC2302, HCC827, H2023, and H1355 were harvested. Cell lysates were prepared by addition of 0.3N hydrochloric acid then 450nM Tris (pH=8) and metabolites were analyzed using the Glutamine/Glutamate Glo Assay (Promega; J8021) per manufacturer's instruction.

Drug treatment of cells 393P-Zeb1 inducible murine NSCLC cells were treated with AXL inhibitor, bemcentinib (0.5 uM), or DMSO for total 24h (8h pretreatment with bemcentinib or DMSO, followed by induction of Zeb1 with doxycycline (2 ug/mL) and an additional 16h drug treatment). Five NSCLC cell lines with varying levels of ACE2 were treated with hydroxychloroquine sulfate (Sigma) for 48h. Cell lysates were harvested for western blot or RPPA analysis. Antibodies used for western analysis include ACE2 (MA5-32307, ThermoFisher), GLUL (80636, Cell Signaling Technology), Vimentin (3932, Cell Signaling Technology), ZEB1 (3396, Cell Signaling Technology), and vinculin (Sigma, V9131) as a loading control. The cell line drug screening data was generated internally. Three measurements were performed for each drug at each concentration to produce dose response data and determine IC50 value.

Protein lysates from TCGA LUAD, NSCLC cell lines, and Calu-1 or 393P cells treated with bemcentinib were quantified and protein arrays were printed and stained 98 . Images were quantified with MicroVigene 4.0 (VigeneTech, Carlisle, MA). The spot-level raw data were processed with the R package SuperCurve suite, which returns the estimated protein concentration (raw concentration) and a quality control score for each slide, as described previously 98 . Only slides with a quality control score of >0.8 were used for downstream analysis. The raw concentration data were normalized by median-centering each sample across all the proteins to correct loading bias.

Total RNA from 55 NSCLC, 30 SCLC, and 49 HNSCC cell lines were analyzed with Affymetrix miRNA 4.0 arrays. The expression data of a curated list of miR-200 family members (hsa-miR-200b-5p, hsa-miR-200b-3p, hsa-miR-200c-5p, hsa-miR-200c-3p, hsa-miR-200a-5p, hsa-miR-200a-3p, hsa-miR-429, hsa-miR-141-5p, hsa-miR-141-3p) known to be involved with EMT in NSCLC 78 were compared with ACE2 expression data.

A total of 225 metabolites were profiled in CCLE upper aerodigestive tract cell lines using liquid chromatography-mass spectrometry (LC-MS) 84 . We compared ACE2 mRNA expression to abundance of metabolites.

To generate the predicted ZEB1 (E-Box) binding sites on the ACE2 promoter, the promoter sequence for human ACE2 was downloaded and used in the matrix profile search on the JASPAR web portal 80 . For the search, the vertebrate database selecting ZEB1 binding motifs were selected to search through the promoter sequence of ACE2 with a relative profile score threshold score cutoff of 80% or higher. The resulting sites were ranked and accordingly the highest-scoring motifs were annotated on the promoter segment using Snapgene.

Raw data for single cell datasets were downloaded from GEO data base and processed using the Seurat Package v2.3.1 99 . First the raw read counts were normalized and scaled using "NormalizeData" and "ScaleData" function. The most variable genes were selected using the "FindVariableGenes" function with default parameters, and principle component analysis (PCA) were performed on these variable genes. We selected the first N principle components that account for at least 80% of the total variances to perform the tSNE transformation. For each genes, the expression status is defined as positive if the cell has non-zero expression value, or negative otherwise. For GSE122960, samples were grouped in to donor samples (including GSM3489182, GSM3489187, GSM3489189, GSM3489191 and GSM3489193) and fibrotic samples (including GSM3489183, GSM3489184, GSM3489188, GSM3489190, GSM3489192, GSM3489194, GSM3489196 and GSM3489198). Each group was subsampled to 20,000 total cells. EMT score was calculated based on the EMT signature as described previously 69, 100 . Cellspecific expression of SFTPC (alveolar type II cells), FOXJI, PIFO (ciliated cells), and SCGB1A1 (club cells) were visualized in tSNE feature plots to identify epithelial clusters containing ACE2-positive cells.

Before performing any analyses, datasets were screened for data quality. One example of a dataset used in these analyses is the NCIs TCGA, a landmark cancer genomics program that characterized over 20,000 primary cancer and adjacent normal tissues from 33 different cancer types. This data is publicly available to the research community for the purpose of investigating novel hypotheses. RNAseq data was inspected for total read counts across all samples as a quality check for library size. Furthermore, datasets were excluded from our analyses due to highly volatile total read counts. In both microarray and RNAseq datasets, Principal Component Analysis (PCA) using all features were performed to make sure no outlier samples were present. When distinct grouping information was included (i.e., Control vs. Infected; Positive vs. Negative etc.), we performed PCA analysis to make sure there was a good separation in the PCA plot. In addition to data quality assessments, we also considered sample size for each individual dataset with a minimum of three samples per group required for further analyses.

The public microarray gene expression data were directly downloaded in the original processed data format from the Gene Expression Omnibus (GEO) site. For single cell RNAseq data, we used the read counting and unique molecular identifier (UMI) count data matrices in GEO. No additional data filtering steps were applied. All the TCGA data used was level 3 processed data. Data quality across datasets is not comparable and contains significant batch effects, especially with the use of different technologies. Therefore, datasets were not combined and all analyses were performed on individual datasets.

All statistic and bioinformatics analyses were performed using R. Paired and un-paired twosample t-tests were used for two group comparisons on paired and unpaired experimental design experiments. Pearson and Spearman correlations were used for correlating genomic and proteomic measurements, as well as correlating drug-screening data. In all the analyses, p<0.05 was considered statistically significant.

The drug-target constellation map (DTECT map) was generated based on drug screening data using a suite of R packages, including ggplot2, ggraph and igraph. A list of drugs was selected based on Spearman coefficient ( >0.3) and p value (<0.1) and only targets with more than 5 associated drugs were shown in the figure.

Publicly available data were obtained from GEO datasets: GSE122960, GSE131391, GSE103322, GSE42127, GSE122960, GSE130148, GSE138693, GSE121600, GSE49644, GSE61395, GSE114647, GSE75602, GSE147507, GSE15741, GSE150819, GSE154770, GSE32465 (GSM1010809). Figure 1 . The SARS-CoV2 receptor, ACE2, is expressed by epithelial cells in cancer models. a, Schematic depicting an overview of the strategy to investigate ACE2 biology in the context of EMT using cancer cell lines and tumor samples before applying to SARS-CoV-2-infected samples to develop our hypotheses. b, ACE2 and TMPRSS2 expression and EMT score in aerodigestive and lung cancer cell lines (ACE2 vs. EMT score, P<0.0001 for all) and c, in patient tumor biopsies (ACE2 vs, EMT score, P<0.0001 for all). TCGA sets (LUAD and HNSC) refer to lung adenocarcinoma and head/neck squamous cell carcinoma, respectively. The BATTLE-1, BATTLE-2, and PROSPECT trials include only NSCLC. Rho values are listed in Table 1 . ACE2 repression by EMT in lung cancer cells. a, ACE2, EMT score, EMT group (epithelial or mesenchymal), CDH1, and ZEB1 expression with miR200 family miRNAs in NSCLC, SCLC and HNSCC cell lines. b, Venn diagrams demonstrating miRNAs correlated with ACE2 expression in both NSCLC and SCLC cell lines (upper) and TCGA LUAD and HNSC tumor biopsies (lower). RNAseq data is shown as normalized relative gene expression. c,d,, Expression of ACE2 (c) and ZEB1(d) following induction of EMT by TGFβ treatment in H358 and HCC827 NSCLC cell lines. e, Expression of ACE2 and ZEB1 in NSCLC and HNSCC cell lines. f, Expression of Ace2 in 393P murine lung adenocarcinoma cells with Zeb1 overexpression. g,h, Cell surface expression of ACE2 (g) and Vimentin (h) in HCC827 cells with constitutive overexpression of ZEB1. i, ACE2, TMPRSS2 and GLUL expression in NSCLC cell lines with acquired resistance to EGFR TKIs that occurred through EMT but not when resistance occurred through EGFR T790M resistance mutations. RNAseq data is shown as normalized relative gene expression. 

A novel coronavirus outbreak of global health concern

A Novel Coronavirus from Patients with Pneumonia in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirusinduced lung injury

Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma

Comprehensive genomic characterization of head and neck squamous cell carcinomas

A 12-gene set predicts survival benefits from adjuvant chemotherapy in nonsmall cell lung cancer patients

The BATTLE trial: personalizing therapy for lung cancer

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer

Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers

Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants

Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells

The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers

The YAP/FOXM1 axis regulates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression

Generation of human bronchial organoids for SARS-CoV-2 research

In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age

Characterizing smoking-induced transcriptional heterogeneity in the human bronchial epithelium at single-cell resolution

Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer

Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis

A cellular census of human lungs identifies novel cell states in health and in asthma

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

Distinct properties of cell-type-specific and shared transcription factor binding sites

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein

Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses

AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling

helps facilitate new clinical trial for COVID-19

AS POTENTIAL TREATMENT FOR COVID-19 THROUGH NEW NATIONAL UK GOVERNMENT CLINICAL TRIAL INITIATIVE

Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection

Smell and taste dysfunction in patients with COVID-19

Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut

Tuft Cells-Systemically Dispersed Sensory Epithelia Integrating Immune and Neural Circuitry

Skn-1a (Pou2f3) specifies taste receptor cell lineage

Pou2f3/Skn-1a is necessary for the generation or differentiation of solitary chemosensory cells in the anterior nasal cavity

Skn-1a/Pou2f3 functions as a master regulator to generate Trpm5-expressing chemosensory cells in mice

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1-7/MAS-1-dependent pathways

Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition

New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2

Genetic dissection of the miR-200-Zeb1 axis reveals its importance in tumor differentiation and invasion

The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression

Proteomic and Metabolomic Characterization of COVID-19

Metabolic Reprogramming of Host Cells in Response to Enteroviral Infection

Glutamine and glutaminolysis are required for efficient replication of infectious spleen and kidney necrosis virus in Chinese perch brain cells

Glutamine metabolism is essential for human cytomegalovirus infection

Vaccinia virus requires glutamine but not glucose for efficient replication

Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix

Inflammatory and Fibrinolytic System in Acute Respiratory Distress Syndrome

New insights into the mechanisms of pulmonary edema in acute lung injury

Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail

miR-200b/c attenuates lipopolysaccharide-induced early pulmonary fibrosis by targeting ZEB1/2 via p38 MAPK and TGF-beta/smad3 signaling pathways

Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis

Mortality rate and gender differences in COVID-19 patients dying in Italy: A comparison with other countries

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Medical changes in preformed host arteries involved in a tumor--a morphometric study of gastric, colonic, and pancreatic carcinomas in man

Giving AXL the axe: targeting AXL in human malignancy

Roles for claudins in alveolar epithelial barrier function

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

JASPAR 2020: update of the open-access database of transcription factor binding profiles

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

The landscape of cancer cell line metabolism

A Pharmacological Interactome between COVID-19 Patient Samples and Human Sensory Neurons Reveals Potential Drivers of Neurogenic Pulmonary Dysfunction

R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer

Acute disseminated paracoccidioidomycosis. Septic shock

Sex difference and smoking predisposition in patients with COVID-19

Functional cooperation between Snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition

Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Antiviral Screening of Multiple Compounds against Ebola Virus

Closes Recruitment Into Trial Assessing Bemcentinib In Covid-19 Patients

Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients

Drug repurposing screens reveal cell-type-specific entry pathways and FDAapproved drugs active against SARS-Cov-2

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1

Exploring nonlinear feature space dimension reduction and data representation in breast Cadx with Laplacian eigenmaps and t-SNE

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer

We wish to acknowledge the patients impacted by the COVID-19 pandemic, along with their loved ones, as well as the first responders, healthcare staff, and essential workers who worked tirelessly and selflessly during this devastating period. We thank C.E.S. for graphical elements and David M. Aten for assistance with medical illustrations. We would like to thank P.M.G.,